XNK Therapeutics to present at Redeye's Regenerative Medicine/Cell Therapy event on February 23

For more information, please contact: For more information, please contact: Johan Liwing, CEO, XNK Therapeutics Tel: +46 706 70 36 75 E-mail:[email protected] About XNK Therapeutics AB XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company is at the forefront of the development of autologous NK cell-based products using its proprietary...

For more information, please contact:

Johan Liwing, CEO, XNK Therapeutics

Tel: +46 706 70 36 75

E-mail: [email protected]

About XNK Therapeutics AB

XNK Therapeutics is a clinical stage, immunotherapy company focusing its efforts on preventing and treating cancer by developing novel NK cell-based therapies. The company is at the forefront of the development of autologous NK cell-based products using its proprietary technology platform. The company's platform technology and lead investigational candidate drug was developed specifically to target cancers, including settings where allogeneic cell products are not readily applicable. The Company's objective is for its investigational candidate drug and proprietary platform technology to constitute key components in the cancer treatments of tomorrow. XNK Therapeutics is headquartered in Stockholm, Sweden. For more info, please visit www.xnktherapeutics.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/xnk-therapeutics-ab/r/xnk-therapeutics-to-present-at-redeye-s-regenerative-medicine-cell-therapy-event-on-february-23,c3511424

The following files are available for download: